TY - JOUR
T1 - Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ3 (PPAR γ3)-selective antagonists based on the helix12-folding inhibition hypothesis
AU - Ohashi, Masao
AU - Gamo, Kanae
AU - Tanaka, Yuta
AU - Waki, Minoru
AU - Beniyama, Yoko
AU - Matsuno, Kenji
AU - Wada, Jun
AU - Tenta, Masafumi
AU - Eguchi, Jun
AU - Makishima, Makoto
AU - Matsuura, Nobuyasu
AU - Oyama, Takuji
AU - Miyachi, Hiroyuki
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid for JSPS Fellows Grant Number 12J07435 , a grant from the Uehara Memorial Foundation , and a grant for Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Publisher Copyright:
© 2014 Elsevier Masson SAS.
PY - 2015/1/27
Y1 - 2015/1/27
N2 - Peroxisome proliferator-activated receptor γ3 (PPARγ3) antagonists are candidates for treatment of type 2 diabetes, obesity and osteoporosis. However, few rational design strategies are currently available. Here, we utilized the helix12 (H12)-folding inhibition hypothesis, in combination with our previously determined X-ray crystal structure of PPARγ3 agonist MEKT-21 (6) complexed with the PPARγ3 ligand-binding domain, to design and develop a potent phenylalkynyl amide-type PPARγ3 antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6. Since 9i retained very weak, but distinct, PPARγ3 agonist activity, we next modified the distal benzene ring of 9i, aiming to delete the residual PPARγ3 agonist activity while retaining the antagonist activity. Introduction of a chlorine atom at the 2-position of the distal benzene ring afforded 9p, which exhibited potent, PPARγ3-selective full antagonist activity without detectable agonist activity. We found that 9p stabilized the corepressor-PPARγ3 complex and suppressed basal PPARγ3 activity. This compound showed anti-adipogenesis activity at the cellular level. This agonist-antagonist switching concept based on the H12-folding inhibition hypothesis should also be applicable for designing other classes of PPARγ3 full antagonists.
AB - Peroxisome proliferator-activated receptor γ3 (PPARγ3) antagonists are candidates for treatment of type 2 diabetes, obesity and osteoporosis. However, few rational design strategies are currently available. Here, we utilized the helix12 (H12)-folding inhibition hypothesis, in combination with our previously determined X-ray crystal structure of PPARγ3 agonist MEKT-21 (6) complexed with the PPARγ3 ligand-binding domain, to design and develop a potent phenylalkynyl amide-type PPARγ3 antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6. Since 9i retained very weak, but distinct, PPARγ3 agonist activity, we next modified the distal benzene ring of 9i, aiming to delete the residual PPARγ3 agonist activity while retaining the antagonist activity. Introduction of a chlorine atom at the 2-position of the distal benzene ring afforded 9p, which exhibited potent, PPARγ3-selective full antagonist activity without detectable agonist activity. We found that 9p stabilized the corepressor-PPARγ3 complex and suppressed basal PPARγ3 activity. This compound showed anti-adipogenesis activity at the cellular level. This agonist-antagonist switching concept based on the H12-folding inhibition hypothesis should also be applicable for designing other classes of PPARγ3 full antagonists.
UR - http://www.scopus.com/inward/record.url?scp=84910645520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910645520&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2014.11.017
DO - 10.1016/j.ejmech.2014.11.017
M3 - Article
C2 - 25461311
AN - SCOPUS:84910645520
SN - 0223-5234
VL - 90
SP - 53
EP - 67
JO - CHIM.THER.
JF - CHIM.THER.
ER -
